Full-Time
Compounding Team Assistant
Posted on 8/20/2026
Auxilium Health
11-50 employees
Biomaterial platform for infection-preventive wound care
Compensation Overview
CA$40k/yr
Oshawa, ON, Canada
In Person
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Auxilium Health
See people who can refer or advise you
- A high school diploma is required.
- Previous experience in an office or pharmacy environment is an asset.
- The employee must demonstrate strong organizational skills, attention to detail, and problem-solving skills.
- The employee must be willing to learn.
- The employee must be able to lift 25-pound boxes around an office environment and 60 pounds occasionally with assistance.
- Support the Compounding Team in preparing medication products, including sterile filtration testing, particulate inspection of prefilled pumps, and preparation reconciliation paperwork.
- Print and affix labels to compounded preparations, including ophthalmic drops, injections, antibiotics, antifungals, antivirals, prefilled syringes, and pumps.
- Package drug products according to health and safety standards, including Credo Cubes with temperature data loggers and bags.
- Process, fill, and bill compounded preparation orders.
- Maintain an inventory of supplies and drug preparations using computer software and tools.
- Arrange and schedule compounded product deliveries to patient care centers and facilities.
- Scan and file documentation.
- Respond flexibly to production changes and team needs.
- Follow documentation and safety protocols.
- Adhere to health and safety policies and regulations.
- Maintain a clean, organized workspace and routinely clean designated areas.
- Assist the Compounding Team with other assigned tasks.
- Knowledge of Zoho Inventory, Microsoft Office, and Google G Suite is preferred.
Auxilium Health develops biomaterials for proactive wound care that combine therapeutics and diagnostics to prevent infections. Its main product, Aux-Shield, is a skin-mimicking biomaterial that kills individual bacteria to stop biofilm formation, while Aux-Color is a diagnostic that changes color to show a wound’s healing stage. The platform's theranostic approach distinguishes it from typical wound-care products by both treating infection risk and signaling healing progress. The company aims to shift wound care from reactive to preventive, pursue FDA clearance, and work with hospitals and clinics to reduce chronic wounds and related costs through a reimbursement-based model.
Company Size
11-50
Company Stage
Seed
Total Funding
$5.4M
Headquarters
Akron, Ohio
Founded
2022
Get referred to Auxilium Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 14, 2026 seed financing added $3.4 million and doubled funding since pre-seed.
- The team doubled in 2025-2026, signaling hiring momentum around Cleveland headquarters.
- NSF, Ohio Department of Development, and strategic investors validate the platform.
What critics are saying
- Organogenesis, MiMedx, Smith & Nephew, and Kerecis already dominate wound biologics sales.
- FDA clearance and first-in-human studies remain unproven, leaving 2027 revenue dependent on milestones.
- If Aer misses infection-prevention endpoints, Auxilium loses reimbursement logic and likely the company.
What makes Auxilium Health unique
- Aer mimics extracellular matrix to resist bacterial attachment without antibiotics, unlike legacy wound dressings.
- Cleveland Clinic's Global Innovation Center anchors clinical access, talent, and translational credibility.
- Auxilium combines wound repair, bone regeneration, and localized delivery in one biomaterial platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -8%2 year growth
↓ -21%Auxilium Health raises oversubscribed $3.4 million seed round to advance Aer biomaterial platform. July 14, 2026 Auxilium Health has closed an oversubscribed $3.4 million seed financing, approximately one year after its pre-seed round, to accelerate development of its Aer(TM) biomaterial platform toward FDA clearance and first-in-human clinical studies. The financing was backed by both existing and new regional and strategic investors, more than doubling the company's previous funding and supporting continued expansion of its research and development efforts. Auxilium is developing a new class of bioaerogels designed to address one of the longstanding challenges in biomaterials: preventing bacterial colonization while promoting tissue regeneration. Rather than relying on antibiotics, the company's Aer(TM) platform is engineered to mimic the body's extracellular matrix, resisting bacterial attachment while encouraging regenerative cells to populate the material. The new capital will fund advancement of the company's lead product through regulatory development, expand its scientific team, and support additional research. Over the past year, Auxilium said it has doubled its full-time workforce, recruiting researchers and scientists to its Cleveland headquarters. "Last year, the question was whether the science was real. This year, it's how fast we can get it to patients," said Isaiah Kaiser, PhD, Founder and CEO of Auxilium Health. "We're grateful to our investors and partners who believe in the science and the team behind what we're building." Headquartered at the Cleveland Clinic's Global Innovation Center, Auxilium Health develops biomaterials for wound repair, bone regeneration, and localized therapeutic delivery. The company is also supported by the National Science Foundation, the Ohio Department of Development, and the Polymer Industry Cluster.
Cleveland-based Auxilium Health has closed an oversubscribed $3.4 million seed round to advance its Aer™ biomaterial platform towards FDA clearance and first-in-human studies. The funding, raised one year after the company's pre-seed round, more than doubles Auxilium's previous raise and comes from returning and new regional and strategic investors. Auxilium's Aer™ platform is an engineered matrix that mimics the body's extracellular matrix, designed to resist bacterial attachment whilst welcoming regenerative cells without using antibiotics. The company's full-time team has doubled over the past year, attracting researchers and scientists to Cleveland. Headquartered at the Cleveland Clinic's Global Innovation Centre, Auxilium is supported by the National Science Foundation, the Ohio Department of Development, and the Polymer Industry Cluster.
Auxilium Health closes oversubscribed $3.4 million seed round to advance its Aer(TM) biomaterial platform. Science · JUL 14, 2026 PR Newswire CLEVELAND, July 14, 2026 /PRNewswire/ - Auxilium Health today announced the close of an oversubscribed $3.4 million seed round, a year after closing its... CLEVELAND, July 14, 2026 /PRNewswire/ - Auxilium Health today announced the close of an oversubscribed $3.4 million seed round, a year after closing its pre-seed, to advance its Aer(TM) biomaterial platform toward FDA clearance and first-in-human studies. Backed by returning and new regional and strategic investors, the round more than doubles the company's prior raise and reflects growing conviction in both the technology and the progress behind it. For nearly four decades, biomaterials have tried to win what surgeons and scientists call the "race for the surface," the contest between a patient's healing cells and bacteria to colonize a material first, by killing bacteria after they arrive. Auxilium takes a different approach. Its Aer(TM) platform is an engineered matrix-like product that mimics the body's own extracellular matrix, built to win that race structurally by resisting bacterial attachment while welcoming regenerative cells, all without relying on antibiotics. The new capital will advance the company's lead product toward FDA clearance and into first-in-human use while deepening the team and the research behind it. Over the last year, Auxilium's full-time team has doubled, attracting top researchers and scientists to relocate to Cleveland to join the mission. "Last year, the question was whether the science was real. This year, it's how fast we can get it to patients," said Isaiah Kaiser, PhD, Founder and CEO of Auxilium Health. "We're grateful to our investors and partners who believe in the science and the team behind what we're building. Their confidence lets us move with the urgency this problem deserves." About Auxilium Health Auxilium Health develops a new class of bioaerogels that reduce the risk of bacterial colonization and guide tissue regeneration. Its Aer(TM) platform spans wound repair, bone regeneration, and localized delivery, with a lead product advancing toward FDA clearance and clinical studies. Headquartered at the Cleveland Clinic's Global Innovation Center, the company is supported by the National Science Foundation, the Ohio Department of Development, and the Polymer Industry Cluster. Regeneration begins at the surface. Media Contact Lindsey Dinneen Director of Marketing & Engagement Project Medtech [email protected] SOURCE Auxilium Health Published by News Desk · WeeklyReviewer The WeeklyReviewer news desk monitors breaking developments around the clock - sourcing, verifying, and publishing real-time industry news across business, technology, politics, science, sports, and world affairs. Every story that comes through the Live Wire is reviewed for accuracy before publication, keeping our readers ahead of the curve without the noise.
Auxilium Health closes $1.5M in funding; secures additional $275K grant from the National Science Foundation.
Auxilium Health announced the closing of an oversubscribed $1.5 million pre-seed funding round, surpassing its $1.2 million target, led by regional investors in Ohio. Additionally, the company secured a $275k grant from the National Science Foundation, highlighting national validation of their biomaterial technology. CEO Isaiah Kaiser expressed gratitude for the support, emphasizing the funding's role in advancing their biomaterial platform for skin tissue regeneration and infection management.